1. Charles L,Sawyers 美国 Memorial Sloan-Kettering Cancer Center 2009拉斯克奖;2010美国科学院院士;2008美国医学院院士 The neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1
2. 赵玉沛 中国 中国医学科学院 中国科学院院士 Enhancer reprogramming: critical roles in cancer and promising therapeutic strategies
3. Rustgi, Anil K. 美国 Columbia University 2019美国医学院院士 Squamous cell cancers of the aero-upper digestive tract: A unified perspective on biology, genetics,..
4. Scott W. Lowe 美国 Memorial Sloan Kettering Cancer Center 2017美国科学院院士;2019美国医学院院士 Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
5. 俞书宏 中国 中国科学技术大学 教授 中国科学院院士 Biomineralization-Tuned Nanounits Reprogram the Signal Transducer and Activator of Transcription 3 S..
6. 徐国良 中国 中国科学院 中国科学院院士 TET2-STAT3-CXCL5 nexus promotes neutrophil lipid transfer to fuel lung adeno-to-squamous transition
7. Benjamin G. Neel 美国 New York University 2022美国科学院院士 Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer
8. 徐国良 中国 中国科学院 中国科学院院士 EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation
9. 李林 中国 中国科学院 中国科学院院士 Oxidative stress-triggered Wnt signaling perturbation characterizes the tipping point of lung adeno-..
10. Bin hua P,Zhou 美国 University of Kentucky Epithelial-mesenchymal transition promotes metabolic reprogramming to suppress ferroptosis
11. 曹亚 中国 中南大学 Multiple roles of branched-chain amino acid metabolism in tumour progression
12. Pierre,Hainaut 法国 University of Grenoble Alpes Transcriptional regulation by LKB1 in lung adenocarcinomas: Exploring oxidative stress, neuroglial a..
13. David S,Hong 美国 University of Texas MD Anderson Cancer Center Impact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated..
14. James G,Christensen 美国 LA JOLLA Laboratory Impact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated..
15. John V,Heymach 美国 University of Texas MD Anderson Cancer Center Impact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated..
16. Gary,Middleton 英国 University of BIRMINGHAM A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer
17. Sanjay,Popat 英国 ROYAL MARSDEN Hospital A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer
18. Charles,Swanton 英国 University College London A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer
19. 翁杰敏 中国 华东师范大学 院长教授 Targeting AKT as a promising strategy for SOX2-positive, chemoresistant osteosarcoma
20. 肖建如 中国 海军军医大学 主任医师 Targeting AKT as a promising strategy for SOX2-positive, chemoresistant osteosarcoma